Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
OCREVUS: Up to 11 Years of Clinical Efficacy and Safety Data in RMS*3,4.

Now with two convenient administration options, patients have a chance to benefit from OCREVUS in the way best suited to their lifestyles1,2

*All-exposure population across 13 clinical trials (phase II and III CTP and associated OLE periods plus VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, LIBERTO, CONSONANCE, CHIMES
and OLERO). 
CTP, controlled-treatment period; OLE, open-label extension; RMS, relapsing multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.
OCREVUS® is a recombinant humanised monoclonal antibody that selectively targets and depletes CD20-expressing B cells1
Click here to find the contact details of your local Roche representative.

References:

  1. OCREVUS SC Summary of Product Characteristics
  2. OCREVUS IV Summary of Product Characteristics
  3. Hauser SL et al. ECTRIMS 2024; Poster P1664. 
  4. Hauser SL et al. ECTRIMS 2024; Poster P300. 
  5. Newsome SD et al. ACTRIMS 2025; Presentation P089
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.